Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Fneurology%2Feptinezumab-in-chronic-migraine-and-medication-overuse-headache%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=34.225.194.102&categories=Conference+Report+Article%7CHeadache+and+Pain%7CNeurology%7CEAN+2020%7CHeadache+%26amp%3B+Migraine): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Eptinezumab in chronic migraine and medication-overuse headache - Medical Conferences

Home > Neurology > EAN 2020 > Headache and Pain > Eptinezumab in chronic migraine and medication-overuse headache

Eptinezumab in chronic migraine and medication-overuse headache

Presented By
Prof. Hans-Christoph Diener, Medical Faculty of the University Duisburg-Essen, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
EAN 2020
Trial
Phase 3, PROMISE-2

In the pivotal PROMISE-2 study, eptinezumab was efficacious in patients with chronic migraine and medication-overuse headache (MOH). After 12 weeks, the eptinezumab group had a greater reduction in migraine days than the placebo group. Efficacy was noted from day 1 and sustained through 24 weeks [1].

In PROMISE-2, 1,072 chronic migraine patients participated, 431 of whom had a dual diagnosis of chronic migraine and MOH. Participants were randomised to eptinezumab 100 mg, 300 mg, or placebo for 2 intravenous doses administered every 12 weeks. Eptinezumab is an anti-calcitonin gene-related peptide monoclonal antibody. MOH patients were equally distributed in these 3 groups. During the 28-day baseline period, MOH patients experienced a mean 16.7 migraine days.

Efficacy of eptinezumab versus placebo on day 1 through 7 was lower with eptinezumab than placebo. On baseline, about 60% of participants experienced migraine; on day 1, this rate was 27.8% (100 mg); 30.1% (300 mg); and 45.5% (placebo). In all of the first 12 weeks of intervention, eptinezumab-treated patients experienced greater reductions in monthly migraine days (MMDs) than placebo patients (100 mg, -8.2; 300 mg, -8.5; placebo, -5.2). About twice as many patients in the eptinezumab groups were ≥50% (60.4%; 61.9%; 34.5%) or ≥75% migraine responders (27.3%; 29.9%; 14.5%). Results were similar during weeks 13-24.

  1. Diener H-C, et al. Abstract EPR1090, EAN 2020.

 



Posted on